Insmed stock surges over 120% as its oral candidate for bronchiectasis reaches Phase 3 trial goals. The company plans to file FDA application in Q4 2024. Read more here.
Novavax stock surges as Sanofi deal brings upgrades seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.